Showing results (1311-1320 of 1,337) with videos related to

Sort By:
Pageof 134
The Science of the Total Environment|September 5, 2024
Bioaccessibility and bioavailability assessment of cadmium in rice: In vitro simulators with/without gut microbiota and validation through in vivo mouse and human dataFei-Fei Xu, Ying-Si Chen, Xiu-Qin Lin, et al.
Cell Proliferation|December 21, 2023
Requirements for human natural killer cellsShuaishuai Niu, Chengxiang Xia, Dehao Huang, et al.
World Journal of Pediatrics : WJP|February 23, 2025
Development and validation of the Parent-Reported Indicator of Developmental Evaluation for Chinese Children (PRIDE) toolSai-Shuang Wu, Hao Pan, Radley Christopher Sheldrick, et al.
Drug Discovery Today|June 18, 2013
Agmatine: clinical applications after 100 years in translationJohn E Piletz, Feyza Aricioglu, Juei-Tang Cheng, et al.
BMC Cancer|April 17, 2025
A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancerYibo Gao, Ping Hu, Ning Wu, et al.
Journal of Hepatology|February 9, 2024
Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiologyXiao-Ning Wu, Meng-Zhou Wang, Nan Zhang, et al.
Frontiers in Oncology|September 5, 2019
Trends of Postoperative Radiotherapy for Completely Resected Non-small Cell Lung Cancer in China: A Hospital-Based Multicenter 10-Year (2005-2014) Retrospective Clinical Epidemiological StudyYu Men, Le Wang, Ye Zhang, et al.
Cancer Medicine|September 24, 2017
Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospital-based multicenter retrospective clinical epidemiological study in China, 2005-2014Yuanqiu Li, Jufang Shi, Shicheng Yu, et al.
American Journal of Respiratory and Critical Care Medicine|July 28, 2022
Risk-stratified Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in ChinaFei Wang, Fengwei Tan, Sipeng Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
Pageof 134